Bio-Rad Laboratories (BIO) stock: analyst price target and their real reliability
Live quote · data updated Oct 14, 2026
Bio-Rad Laboratories · Health Care · ref. ETF XLV · 50 calls · price $363.73
What the company does: Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products.
📈 Bio-Rad Laboratories (BIO) stock price
$363.73+19.2% over range
Oct 14, 25low $241.71 · high $390.34Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
33% recommend buying · 3 analysts
📊 JPI status : Bio-Rad Laboratories has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
⚠️ The stock trades above the median target: it has beaten expectations. The “Hold” reflects conviction on the company, but the remaining quantified upside is low/negative.
🎯 BIO price target & analyst consensus — price $364
The price target · all analysts combined (3 targets)
Highest target · 1 firm of 3$390+7.2%
Median target · of 3 targets$330-9.3%
Lowest target · 2 firms of 3$330-9.3%
Current price$363.73
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: Citigroup — 65% of its targets hit on this sector (128 calls tested). It aims for $330 (-9.3 %), call made on August 6, 2026, maturing on August 6, 2027 (69 d ago).
The 3 reliable analysts
$330-9.3 %
How to read it: the 3 reliable firms are not filtered by optimism — 1 aim above the price, 2 below, hence their $330 median.
The consensus · 3 ratings (last 6 months)
Strong Buy00%
Buy133%
Hold267%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 BIO price target all
All 50 calls, one by one, with our verdict on each firm.
→ See all 50 targets, analyst by analyst💡 The best analysts on BIO most reliable
Their real reliability on BIO, firm by firm: who was right, who was wrong.
→ See their reliability on BIOAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Bio-Rad Laboratories? The JPI assistant answers using our backtest data.
📈 Bio-Rad Laboratories fundamentals: valuation, margins & growth › open the full page
P/E 46.1Net margin 8.6 %Revenue growth -0.1 %Fairly valued
Revenue, net income and margin per year
Revenue Net income · hover a bar for details
2022
marg. -129 %
2023
Rev −5%
2024
Rev −4%
2025
Rev +1%
🔎 Detailed analyses
✅ Historical analyst reliability on BIO
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Barclays ↗ | 100% | +51.5% | 4 |
| Goldman Sachs ↗ | 100% | +36.2% | 2 |
| Deutsche Bank ↗ | 100% | +30.9% | 3 |
| Jefferies ↗ | 83% | +12.0% | 6 |
| Wells Fargo ↗ | 67% | +22.4% | 9 |
| Citigroup ↗ | 55% | +16.9% | 11 |
| UBS ↗ | 50% | -3.9% | 4 |
| RBC Capital ↗ | 17% | -12.2% | 12 |
| Credit Suisse | 0% | -24.4% | 5 |
📊 What $1,000 invested in Bio-Rad Laboratories would be worth › open the full page
In short — $1,000 invested in Bio-Rad Laboratories 10 years ago would be worth $2,301 today, i.e. +9%/yr on average. Best year: 2020 (+59%), worst: 2023 (-31%). Price performance, excluding dividends.
If I'd invested $1,000 in Bio-Rad Laboratories
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $814 | -19% |
| 3 years ago | $628 | -37% |
| 5 years ago | $512 | -49% |
Return by year (Bio-Rad Laboratories)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | 0% | $1,000 (0%) |
| 2025 | -19% | $814 (-19%) |
| 2024 | +12% | $915 (-9%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Bio-Rad Laboratories
Loading news…
📋 All analyst calls on BIO
Filtered on — · ✕ show all
RBC Capital ↗
Aug 7, 26
▲ Outperform · 🎯$390
Price at call : $354.54 — upside +10%
Today : $363.73 — upside +7%
🎯 on BIO : 17% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : Aug 7, 27
matures : Aug 7, 27
■ Neutral neutral · not a buy · 🎯$330
Price at call : $342.43 — gap to target -4%
Today : $363.73 — gap to target -9%
🎯 on BIO : 38% (8 calls matureds) · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
RBC Capital ↗
Aug 5, 26
▲ Outperform · 🎯$370
Price at call : $342.43 — upside +8%
Today : $363.73 — upside +2%
🎯 on BIO : 17% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
Wells Fargo ↗
Aug 5, 26
■ Equal-Weight neutral · not a buy · 🎯$330
Price at call : $342.43 — gap to target -4%
Today : $363.73 — gap to target -9%
🎯 on BIO : 25% (4 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Aug 5, 27
matures : Aug 5, 27
Wells Fargo ↗
May 1, 26
■ Equal-Weight neutral · not a buy · 🎯$290
Price at call : $257.86 — gap to target +12%
Today : $363.73 — gap to target -20%
🎯 on BIO : 25% (4 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : May 1, 27
matures : May 1, 27
■ Neutral neutral · not a buy · 🎯$300
Price at call : $278 — gap to target +8%
Today : $363.73 — gap to target -18%
🎯 on BIO : 38% (8 calls matureds) · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : Apr 7, 27
matures : Apr 7, 27
Wells Fargo ↗
Feb 16, 26
■ Equal-Weight neutral · not a buy · 🎯$320
Price at call : $264.93 — gap to target +21%
Today : $363.73 — gap to target -12%
🎯 on BIO : 25% (4 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Feb 16, 27
matures : Feb 16, 27
▲ Buy · 🎯$375
Price at call : $319.55 — upside +17%
Today : $363.73 — upside +3%
🎯 on BIO : 38% (8 calls matureds) · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : Oct 30, 26
matures : Oct 30, 26
See the other 42 calls, newest to oldest
Wells Fargo ↗
Oct 30, 25
■ Equal-Weight neutral · not a buy · 🎯$340
Price at call : $319.55 — gap to target +6%
Today : $363.73 — gap to target -7%
🎯 on BIO : 25% (4 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Oct 30, 26
matures : Oct 30, 26
RBC Capital ↗
Aug 1, 25
▲ Outperform · 🎯$409
Price at call : $276.8 — upside +48%
Today : $363.73 — upside +12%
Expected +48% · Actual +21% · Reason (≥ +15%) : ✓ Yes
🎯 on BIO : 17% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+20.9%
stock +21% · XLV +22%
matured Aug 1, 26
Wells Fargo ↗
Aug 1, 25
■ Equal-Weight neutral · not a buy · 🎯$265
Price at call : $276.8 — gap to target -4%
Today : $363.73 — gap to target -27%
🎯 on BIO : 25% (4 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Aug 1, 26
matures : Aug 1, 26
Wells Fargo ↗
Jun 9, 25
■ Equal-Weight neutral · not a buy · 🎯$245
Price at call : $230.52 — gap to target +6%
Today : $363.73 — gap to target -33%
🎯 on BIO : 25% (4 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Jun 9, 26
matures : Jun 9, 26
▲ Buy · 🎯$310
Price at call : $240.19 — upside +29%
Today : $363.73 — upside -15%
Expected +29% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 50% (4 calls matureds) · 📊 on Health : 49.2% · +16.9% (124 calls)
+7.4%
stock +7% · XLV +5%
matured May 3, 26
▲ Buy · 🎯$350
Price at call : $240.19 — upside +46%
Today : $363.73 — upside -4%
Expected +46% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 38% (8 calls matureds) · 📊 on Health : 57% · +17.6% (128 calls)
+7.4%
stock +7% · XLV +5%
matured May 3, 26
RBC Capital ↗
May 2, 25
▲ Outperform · 🎯$392
Price at call : $240.19 — upside +63%
Today : $363.73 — upside +8%
Expected +63% · Actual +7% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 17% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
+7.4%
stock +7% · XLV +5%
matured May 2, 26
Wells Fargo ↗
Apr 17, 25
■ Equal-Weight neutral · not a buy · 🎯$270
Price at call : $236.88 — gap to target +14%
Today : $363.73 — gap to target -26%
🎯 on BIO : 25% (4 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Apr 17, 26
matures : Apr 17, 26
Wells Fargo ↗
Feb 12, 25
■ Equal-Weight neutral · not a buy · 🎯$345
Price at call : $306.36 — gap to target +13%
Today : $363.73 — gap to target -5%
🎯 on BIO : 25% (4 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Feb 12, 26
matures : Feb 12, 26
RBC Capital ↗
Jan 14, 25
▲ Outperform · 🎯$481
Price at call : $341.79 — upside +41%
Today : $363.73 — upside +32%
Expected +41% · Actual -6% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 17% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-5.8%
stock -6% · XLV +12%
matured Jan 14, 26
RBC Capital ↗
Dec 9, 24
▲ Outperform · 🎯$481
Price at call : $345.6 — upside +39%
Today : $363.73 — upside +32%
Expected +39% · Actual -11% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 17% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-10.9%
stock -11% · XLV +4%
matured Dec 9, 25
▲ Buy · 🎯$450
Price at call : $368.42 — upside +22%
Today : $363.73 — upside +24%
Expected +22% · Actual -15% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 38% (8 calls matureds) · 📊 on Health : 57% · +17.6% (128 calls)
-15.5%
stock -15% · XLV -2%
matured Oct 31, 25
RBC Capital ↗
Oct 31, 24
▲ Outperform · 🎯$469
Price at call : $368.42 — upside +27%
Today : $363.73 — upside +29%
Expected +27% · Actual -15% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 17% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-15.5%
stock -15% · XLV -2%
matured Oct 31, 25
▲ Buy · 🎯$400
Price at call : $337.69 — upside +18%
Today : $363.73 — upside +10%
Expected +18% · Actual -12% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 38% (8 calls matureds) · 📊 on Health : 57% · +17.6% (128 calls)
-11.8%
stock -12% · XLV -6%
matured Oct 1, 25
Wells Fargo ↗
Aug 27, 24
■ Equal-Weight neutral · not a buy · 🎯$340
Price at call : $328.75 — gap to target +3%
Today : $363.73 — gap to target -7%
🎯 on BIO : 25% (4 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
in progress (365j)
matures : Aug 27, 25
matures : Aug 27, 25
RBC Capital ↗
Aug 16, 24
▲ Outperform · 🎯$401
Price at call : $326.33 — upside +23%
Today : $363.73 — upside +10%
Expected +23% · Actual -13% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 17% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-12.8%
stock -13% · XLV -12%
matured Aug 16, 25
RBC Capital ↗
Aug 2, 24
▲ Outperform · 🎯$401
Price at call : $328.68 — upside +22%
Today : $363.73 — upside +10%
Expected +22% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 17% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-15.8%
stock -16% · XLV -9%
matured Aug 2, 25
■ Neutral neutral · not a buy · 🎯$350
Price at call : $328.68 — gap to target +6%
Today : $363.73 — gap to target -4%
🎯 on BIO : 38% (8 calls matureds) · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : Aug 2, 25
matures : Aug 2, 25
▲ Buy · 🎯$385
Price at call : $268.26 — upside +44%
Today : $363.73 — upside +6%
Expected +44% · Actual -10% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 50% (4 calls matureds) · 📊 on Health : 49.2% · +16.9% (124 calls)
-10.2%
stock -10% · XLV -6%
matured May 8, 25
■ Neutral neutral · not a buy · 🎯$365
Price at call : $322.83 — gap to target +13%
Today : $363.73 — gap to target +0%
🎯 on BIO : 38% (8 calls matureds) · 📊 on Health : 57% · +17.6% (128 calls)
in progress (365j)
matures : Apr 3, 25
matures : Apr 3, 25
▲ Buy · 🎯$420
Price at call : $343.76 — upside +22%
Today : $363.73 — upside +15%
Expected +22% · Actual -18% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 50% (4 calls matureds) · 📊 on Health : 49.2% · +16.9% (124 calls)
-17.6%
stock -18% · XLV -0%
matured Feb 15, 25
RBC Capital ↗
Feb 16, 24
▲ Outperform · 🎯$480
Price at call : $343.76 — upside +40%
Today : $363.73 — upside +32%
Expected +40% · Actual -18% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 17% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-17.6%
stock -18% · XLV -0%
matured Feb 15, 25
▲ Buy · 🎯$395
Price at call : $310.18 — upside +27%
Today : $363.73 — upside +9%
Expected +27% · Actual +5% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 50% (4 calls matureds) · 📊 on Health : 49.2% · +16.9% (124 calls)
+4.9%
stock +5% · XLV +9%
matured Dec 6, 24
Wells Fargo ↗
Aug 7, 23
▲ Overweight · 🎯$525
Price at call : $401.52 — upside +31%
Today : $363.73 — upside +44%
Expected +31% · Actual -19% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 25% (4 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
-18.6%
stock -19% · XLV +10%
matured Aug 6, 24
RBC Capital ↗
Aug 4, 23
▲ Outperform · 🎯$524
Price at call : $401.52 — upside +31%
Today : $363.73 — upside +44%
Expected +31% · Actual -18% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 17% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-18.1%
stock -18% · XLV +10%
matured Aug 3, 24
Credit Suisse
Aug 4, 23
▲ Outperform · 🎯$550
Price at call : $400 — upside +38%
Today : $363.73 — upside +51%
Expected +38% · Actual -18% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 0% (5 calls matureds) · 📊 unranked overall
-17.8%
stock -18% · XLV +11%
matured Aug 3, 24
Wells Fargo ↗
Jun 16, 23
▲ Overweight · 🎯$550
Price at call : $376.56 — upside +46%
Today : $363.73 — upside +51%
Expected +46% · Actual -21% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 25% (4 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
-21.4%
stock -21% · XLV +10%
matured Jun 15, 24
▲ Buy · 🎯$525
Price at call : $366.86 — upside +43%
Today : $363.73 — upside +44%
Expected +43% · Actual -27% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 38% (8 calls matureds) · 📊 on Health : 57% · +17.6% (128 calls)
-26.9%
stock -27% · XLV +7%
matured May 7, 24
RBC Capital ↗
May 8, 23
▲ Outperform · 🎯$531
Price at call : $378.39 — upside +40%
Today : $363.73 — upside +46%
Expected +40% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 17% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-26.0%
stock -26% · XLV +7%
matured May 7, 24
Credit Suisse
May 5, 23
▲ Outperform · 🎯$580
Price at call : $378.39 — upside +53%
Today : $363.73 — upside +59%
Expected +53% · Actual -25% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 0% (5 calls matureds) · 📊 unranked overall
-25.5%
stock -25% · XLV +6%
matured May 4, 24
RBC Capital ↗
Feb 17, 23
▲ Outperform · 🎯$579
Price at call : $483.23 — upside +20%
Today : $363.73 — upside +59%
Expected +20% · Actual -29% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 17% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-28.9%
stock -29% · XLV +10%
matured Feb 17, 24
Credit Suisse
Feb 17, 23
▲ Outperform · 🎯$680
Price at call : $483.23 — upside +41%
Today : $363.73 — upside +87%
Expected +41% · Actual -29% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 0% (5 calls matureds) · 📊 unranked overall
-28.9%
stock -29% · XLV +10%
matured Feb 17, 24
RBC Capital ↗
Dec 7, 22
▲ Outperform · 🎯$565
Price at call : $403.88 — upside +40%
Today : $363.73 — upside +55%
Expected +40% · Actual -23% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 17% (12 calls matureds) · 📊 on Health : 48.8% · +6.8% (201 calls)
-23.2%
stock -23% · XLV -5%
matured Dec 7, 23
Credit Suisse
Oct 28, 22
▲ Outperform · 🎯$640
Price at call : $354.3 — upside +81%
Today : $363.73 — upside +76%
Expected +81% · Actual -24% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 0% (5 calls matureds) · 📊 unranked overall
-24.0%
stock -24% · XLV -7%
matured Oct 28, 23
Credit Suisse
Aug 25, 22
▲ Outperform · 🎯$715
Price at call : $514.63 — upside +39%
Today : $363.73 — upside +97%
Expected +39% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 0% (5 calls matureds) · 📊 unranked overall
-25.8%
stock -26% · XLV +2%
matured Aug 25, 23
▲ Buy · 🎯$700
Price at call : $517.12 — upside +35%
Today : $363.73 — upside +92%
Expected +35% · Actual -25% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 38% (8 calls matureds) · 📊 on Health : 57% · +17.6% (128 calls)
-24.7%
stock -25% · XLV -1%
matured Jul 8, 23
Wells Fargo ↗
Jul 30, 21
▲ Overweight · 🎯$930
Price at call : $739.51 — upside +26%
Today : $363.73 — upside +156%
Expected +26% · Actual -25% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 25% (4 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
-25.1%
stock -25% · XLV -1%
matured Jul 30, 22
▲ Buy · 🎯$750
Price at call : $649.62 — upside +15%
Today : $363.73 — upside +106%
Expected +15% · Actual -4% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 38% (8 calls matureds) · 📊 on Health : 57% · +17.6% (128 calls)
-4.4%
stock -4% · XLV +11%
matured Feb 12, 22
▲ Buy · 🎯$725
Price at call : $628.68 — upside +15%
Today : $363.73 — upside +99%
Expected +15% · Actual -1% · Reason (≥ +15%) : ✗ No
🎯 on BIO : 0% (1 call matured) · 📊 on Health : 48.3% · +10.7% (116 calls)
-0.6%
stock -1% · XLV +14%
matured Feb 5, 22
▲ Buy · 🎯$625
Price at call : $524.89 — upside +19%
Today : $363.73 — upside +72%
Expected +19% · Actual +40% · Reason (≥ +15%) : ✓ Yes
🎯 on BIO : 38% (8 calls matureds) · 📊 on Health : 57% · +17.6% (128 calls)
+40.3%
stock +40% · XLV +25%
matured Jul 31, 21
Wells Fargo ↗
May 21, 20
▲ Overweight · 🎯$525
Price at call : $466.79 — upside +12%
Today : $363.73 — upside +44%
Expected +12% · Actual +27% · Reason (≥ +15%) : ✓ Yes
🎯 on BIO : 25% (4 calls matureds) · 📊 on Health : 47.4% · +5.1% (152 calls)
+27.4%
stock +27% · XLV +25%
matured May 21, 21
Frequently asked questions
Should I buy Bio-Rad Laboratories stock?
This isn't buy advice. For Bio-Rad Laboratories, the analyst consensus is "Hold", with an average price target of $330 (-9% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (4 calls tracked on Bio-Rad Laboratories). We show the numbers — you decide.
Is it too late to buy Bio-Rad Laboratories? How high can it go?
The most bullish analyst target on Bio-Rad Laboratories is $390 (+7% above today's price); the average is $330. That's the upside they see. Check how reliable those analysts have actually been on Bio-Rad Laboratories on our site before trusting it.
Is Bio-Rad Laboratories still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 9 analysts have a real record on Bio-Rad Laboratories, the best hitting 100% over 4 calls. Current consensus: "Hold". Make your call on data, not noise.
What has Bio-Rad Laboratories's past performance been?
Historical returns and a "how much if I had invested" calculator: BIO performance & returns.
BIIB 
VRTX 
REGN 
UNH 
EW 
SRPT 
VEEV 
BSX